Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CUE |
---|---|---|
09:32 ET | 5466 | 1.52 |
09:39 ET | 300 | 1.5 |
09:41 ET | 200 | 1.5 |
09:45 ET | 1120 | 1.48 |
09:48 ET | 100 | 1.48 |
09:50 ET | 200 | 1.47 |
09:52 ET | 348 | 1.48 |
09:54 ET | 2974 | 1.5 |
09:57 ET | 100 | 1.49 |
09:59 ET | 1001 | 1.4898 |
10:03 ET | 100 | 1.48 |
10:24 ET | 7333 | 1.48 |
10:26 ET | 100 | 1.47 |
10:32 ET | 4483 | 1.46 |
10:33 ET | 100 | 1.45 |
10:37 ET | 100 | 1.46 |
10:39 ET | 100 | 1.465 |
10:42 ET | 2230 | 1.46 |
10:46 ET | 100 | 1.47 |
10:48 ET | 100 | 1.46 |
10:50 ET | 9513 | 1.45 |
10:51 ET | 699 | 1.45 |
10:55 ET | 6845 | 1.45 |
10:57 ET | 100 | 1.46 |
11:00 ET | 100 | 1.45 |
11:02 ET | 100 | 1.45 |
11:04 ET | 700 | 1.46 |
11:06 ET | 4243 | 1.45 |
11:08 ET | 100 | 1.47 |
11:11 ET | 300 | 1.47 |
11:13 ET | 600 | 1.47 |
11:15 ET | 8182 | 1.47 |
11:22 ET | 216 | 1.46 |
11:24 ET | 100 | 1.45 |
11:27 ET | 425 | 1.45 |
11:29 ET | 200 | 1.45 |
11:31 ET | 4000 | 1.45 |
11:33 ET | 100 | 1.45 |
11:36 ET | 600 | 1.45 |
11:38 ET | 25898 | 1.479 |
11:40 ET | 800 | 1.47 |
11:42 ET | 25013 | 1.5 |
11:44 ET | 211 | 1.5 |
11:51 ET | 400 | 1.5 |
11:54 ET | 500 | 1.485 |
11:58 ET | 500 | 1.48 |
12:00 ET | 100 | 1.48 |
12:02 ET | 100 | 1.47 |
12:03 ET | 200 | 1.47 |
12:05 ET | 100 | 1.47 |
12:07 ET | 356 | 1.47 |
12:09 ET | 200 | 1.47 |
12:12 ET | 2884 | 1.4699 |
12:14 ET | 100 | 1.46 |
12:16 ET | 100 | 1.46 |
12:18 ET | 350 | 1.4696 |
12:20 ET | 1375 | 1.47 |
12:21 ET | 100 | 1.465 |
12:23 ET | 100 | 1.465 |
12:25 ET | 100 | 1.465 |
12:27 ET | 100 | 1.48 |
12:30 ET | 100 | 1.465 |
12:32 ET | 100 | 1.46 |
12:36 ET | 300 | 1.47 |
12:38 ET | 100 | 1.46 |
12:39 ET | 750 | 1.465 |
12:41 ET | 300 | 1.46 |
12:43 ET | 100 | 1.46 |
12:48 ET | 100 | 1.46 |
12:52 ET | 100 | 1.46 |
12:56 ET | 100 | 1.46 |
12:59 ET | 300 | 1.46 |
01:03 ET | 100 | 1.46 |
01:08 ET | 100 | 1.47 |
01:10 ET | 3200 | 1.4681 |
01:12 ET | 305 | 1.47 |
01:14 ET | 600 | 1.45 |
01:15 ET | 100 | 1.45 |
01:17 ET | 233 | 1.45 |
01:21 ET | 170 | 1.46 |
01:24 ET | 100 | 1.45 |
01:28 ET | 100 | 1.45 |
01:30 ET | 112 | 1.47 |
01:32 ET | 1100 | 1.46 |
01:33 ET | 1200 | 1.465 |
01:35 ET | 100 | 1.46 |
01:37 ET | 441 | 1.46 |
01:42 ET | 100 | 1.45 |
01:46 ET | 200 | 1.45 |
01:51 ET | 100 | 1.45 |
01:53 ET | 100 | 1.455 |
01:55 ET | 2404 | 1.46 |
01:57 ET | 100 | 1.48 |
02:04 ET | 100 | 1.48 |
02:06 ET | 493 | 1.47 |
02:08 ET | 100 | 1.47 |
02:09 ET | 100 | 1.46 |
02:11 ET | 799 | 1.47 |
02:15 ET | 200 | 1.47 |
02:18 ET | 150 | 1.4726 |
02:20 ET | 370 | 1.48 |
02:22 ET | 720 | 1.47 |
02:26 ET | 1997 | 1.46 |
02:29 ET | 100 | 1.48 |
02:36 ET | 100 | 1.48 |
02:38 ET | 100 | 1.46 |
02:40 ET | 200 | 1.48 |
02:42 ET | 100 | 1.48 |
02:45 ET | 100 | 1.46 |
02:51 ET | 100 | 1.48 |
02:56 ET | 138 | 1.48 |
02:58 ET | 1525 | 1.46 |
03:00 ET | 321 | 1.465 |
03:02 ET | 600 | 1.45 |
03:05 ET | 437 | 1.455 |
03:07 ET | 200 | 1.455 |
03:09 ET | 100 | 1.45 |
03:12 ET | 60592 | 1.43 |
03:21 ET | 952 | 1.43 |
03:23 ET | 41195 | 1.43 |
03:27 ET | 100 | 1.42 |
03:30 ET | 1785 | 1.41 |
03:34 ET | 1958 | 1.4 |
03:36 ET | 1000 | 1.39 |
03:38 ET | 3379 | 1.39 |
03:39 ET | 1775 | 1.395 |
03:41 ET | 3374 | 1.3999 |
03:43 ET | 1600 | 1.4 |
03:45 ET | 2000 | 1.4099 |
03:48 ET | 1100 | 1.4007 |
03:50 ET | 4968 | 1.43 |
03:52 ET | 4712 | 1.43 |
03:54 ET | 288 | 1.43 |
03:57 ET | 100 | 1.43 |
03:59 ET | 2189 | 1.42 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Cue Biopharma Inc | 73.0M | -1.3x | --- |
LAVA Therapeutics NV | 78.3M | -1.7x | --- |
Kronos Bio Inc | 57.1M | -0.5x | --- |
Kezar Life Sciences Inc | 60.1M | -0.6x | --- |
BioLine RX Ltd | 54.2M | -0.6x | --- |
Armata Pharmaceuticals Inc | 91.5M | -1.3x | --- |
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $73.0M |
---|---|
Revenue (TTM) | $5.5M |
Shares Outstanding | 48.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.04 |
EPS | $-1.11 |
Book Value | $0.79 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | 13.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -949.87% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.